DTWD1 inhibitors, as listed, focus on modulating the ubiquitination pathway and proteasome activity, indirectly influencing DTWD1's function. Ubiquitination is a process where proteins are tagged with ubiquitin molecules, marking them for degradation by the proteasome. DTWD1, involved in this pathway, can be influenced by altering the dynamics of protein ubiquitination and degradation. Proteasome inhibitors like MG-132 [Z-Leu- Leu-Leu-CHO], Bortezomib, Lactacystin, and Carfilzomib, work by preventing the degradation of ubiquitinated proteins. This leads to an accumulation of these proteins within the cell, indirectly affecting any processes DTWD1 may be involved in. By inhibiting the proteasome, these compounds can impact a variety of cellular processes, including those related to cell cycle regulation, apoptosis, and response to oxidative stress.
On the other hand, inhibitors like MLN 4924 and Ubiquitin E1 Inhibitor, PYR-41 target the ubiquitination process more directly. MLN 4924 inhibits the NEDD8-activating enzyme, which is essential for the neddylation of cullin proteins, a process crucial for the function of some ubiquitin ligases. Ubiquitin E1 Inhibitor, PYR-41, inhibiting the ubiquitin-activating enzyme E1, disrupts the initial step of the ubiquitination cascade. These inhibitors can potentially alter the substrate specificity or the rate of ubiquitination, thereby influencing DTWD1's activity. Inhibitors such as MLN 7243, IXA-001, PR 619, and Ubistatin represent more targeted approaches to modulating ubiquitination. They focus on specific aspects of the ubiquitin-proteasome system, such as inhibiting deubiquitinating enzymes or blocking the recognition of ubiquitinated proteins by the proteasome. By interfering with these mechanisms, they can indirectly modulate the functional role of DTWD1 in the cell. The indirect inhibition of DTWD1 through these diverse chemical inhibitors highlights the complexity of targeting a protein involved in a ubiquitous and multifaceted pathway like ubiquitination. These inhibitors offer a window into the broader regulatory mechanisms that control protein stability and function within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can indirectly affect DTWD1 by inhibiting the degradation of ubiquitinated proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
As a proteasome inhibitor, it could impact DTWD1's role in protein ubiquitination by stabilizing ubiquitin-protein complexes. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
An inhibitor of NEDD8-activating enzyme, affecting ubiquitin-like protein neddylation, potentially impacting DTWD1. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An inhibitor of ubiquitin-activating enzyme E1, which could indirectly modulate DTWD1's involvement in ubiquitination. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
A more selective form of lactacystin, targeting the proteasome and potentially influencing DTWD1-related pathways. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
A newer generation proteasome inhibitor, potentially affecting DTWD1's role in protein ubiquitination. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
A broad-spectrum inhibitor of deubiquitinating enzymes, which may indirectly influence DTWD1's ubiquitination activity. | ||||||